These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

87 related items for PubMed ID: 23500117

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Biphasic vesicles for topical delivery of interferon alpha in human volunteers and treatment of patients with human papillomavirus infections.
    Foldvari M, Badea I, Kumar P, Wettig S, Batta R, King MJ, He Z, Yeboah E, Gaspar K, Hull P, Shear NH.
    Curr Drug Deliv; 2011 May; 8(3):307-19. PubMed ID: 21291377
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy.
    Balan V, Nelson DR, Sulkowski MS, Everson GT, Lambiase LR, Wiesner RH, Dickson RC, Post AB, Redfield RR, Davis GL, Neumann AU, Osborn BL, Freimuth WW, Subramanian GM.
    Antivir Ther; 2006 May; 11(1):35-45. PubMed ID: 16518958
    [Abstract] [Full Text] [Related]

  • 6. Prolonging the half-life of human interferon-alpha 2 in circulation: Design, preparation, and analysis of (2-sulfo-9-fluorenylmethoxycarbonyl)7- interferon-alpha 2.
    Shechter Y, Preciado-Patt L, Schreiber G, Fridkin M.
    Proc Natl Acad Sci U S A; 2001 Jan 30; 98(3):1212-7. PubMed ID: 11158619
    [Abstract] [Full Text] [Related]

  • 7. New treatment of viral genital lesions with low dosage of interferon alpha by oropharyngeal absorption.
    Bastianelli C, Caruso MT, Marcellini GF.
    Clin Ter; 2000 Jan 30; 151(1 Suppl 1):23-8. PubMed ID: 10876963
    [No Abstract] [Full Text] [Related]

  • 8. Liposome associated interferon-alpha-2b functions as an anti-fibrogenic factor in dermal wounds in the guinea pig.
    Ghahary A, Tredget EE, Shen Q, Kilani RT, Scott PG, Takeuchi M.
    Mol Cell Biochem; 2000 May 30; 208(1-2):129-37. PubMed ID: 10939636
    [Abstract] [Full Text] [Related]

  • 9. [Study of the antiviral activity, pharmacokinetics and toxic properties of liposomal form of human alpha-2b interferon administered topically].
    Zolin VV, Agafonova OA, Kolokol'tsov AA, Danilenko ED, Fedosova LK, Gamaleĭ SG, Omigov VV, Fadina VA, Masycheva VI.
    Vestn Ross Akad Med Nauk; 2001 May 30; (5):27-31. PubMed ID: 11510145
    [Abstract] [Full Text] [Related]

  • 10. Multivesicular liposome formulations for the sustained delivery of interferon alpha-2b.
    Qiu J, Wei XH, Geng F, Liu R, Zhang JW, Xu YH.
    Acta Pharmacol Sin; 2005 Nov 30; 26(11):1395-401. PubMed ID: 16225764
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics of aminomethylpropanol in rats following oral and a novel dermal study design.
    Saghir SA, Clark AJ, McClymont EL, Staley JL.
    Food Chem Toxicol; 2008 Feb 30; 46(2):678-87. PubMed ID: 17961896
    [Abstract] [Full Text] [Related]

  • 12. Basis for dosing time-dependent changes in the antiviral activity of interferon-alpha in mice.
    Ohdo S, Wang DS, Koyanagi S, Takane H, Inoue K, Aramaki H, Yukawa E, Higuchi S.
    J Pharmacol Exp Ther; 2000 Aug 30; 294(2):488-93. PubMed ID: 10900223
    [Abstract] [Full Text] [Related]

  • 13. Transdermal delivery of interferon alpha-2B using microporation and iontophoresis in hairless rats.
    Badkar AV, Smith AM, Eppstein JA, Banga AK.
    Pharm Res; 2007 Jul 30; 24(7):1389-95. PubMed ID: 17443396
    [Abstract] [Full Text] [Related]

  • 14. Dermal and transdermal delivery of protein pharmaceuticals: lipid-based delivery systems for interferon alpha.
    Foldvari M, Baca-Estrada ME, He Z, Hu J, Attah-Poku S, King M.
    Biotechnol Appl Biochem; 1999 Oct 30; 30(2):129-37. PubMed ID: 10512792
    [Abstract] [Full Text] [Related]

  • 15. Oral use of interferon therapy in cervical human papillomavirus infection.
    Palomba M, Melis GB.
    Clin Ter; 2000 Oct 30; 151(1 Suppl 1):59-61. PubMed ID: 10876967
    [Abstract] [Full Text] [Related]

  • 16. Lipidization of human interferon-alpha: a new approach toward improving the delivery of protein drugs.
    Yuan L, Wang J, Shen WC.
    J Control Release; 2008 Jul 02; 129(1):11-7. PubMed ID: 18448186
    [Abstract] [Full Text] [Related]

  • 17. Preliminary note on the use of interferon alpha by peroral route in HPV lesions.
    Montevecchi L, Caprio G, Vecchione A.
    Clin Ter; 2000 Jul 02; 151(1 Suppl 1):29-34. PubMed ID: 10876964
    [No Abstract] [Full Text] [Related]

  • 18. Calcium Phosphate Particles as Pulmonary Delivery System for Interferon-α in Mice.
    Morçöl T, Weidner JM, Mehta A, Bell SJD, Block T.
    AAPS PharmSciTech; 2018 Jan 02; 19(1):395-412. PubMed ID: 28752471
    [Abstract] [Full Text] [Related]

  • 19. [Self-assembly and in vitro and in vivo evaluation of spherical crystallized interferon for sustained delivery].
    Shi K, Cui FD, Bi HS, Jiang YB.
    Yao Xue Xue Bao; 2013 Aug 02; 48(8):1333-7. PubMed ID: 24187845
    [Abstract] [Full Text] [Related]

  • 20. Peroral alpha-interferon therapy in HPV-lesions of the lower female genital tract: preliminary results.
    Biamonti A, Cangialosi M, Brozzo R, Vecchione A, Serra GB.
    Clin Ter; 2000 Aug 02; 151(1 Suppl 1):53-8. PubMed ID: 10876966
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.